Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 169

1.

The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases.

Buss DH, Stuart JJ, Lipscomb GE.

Am J Hematol. 1985 Dec;20(4):365-72.

PMID:
3865532
[PubMed - indexed for MEDLINE]
2.

Etiology and incidence of thrombotic and hemorrhagic disorders in Thai patients with extreme thrombocytosis.

Chuncharunee S, Archararit N, Ungkanont A, Jootar S, Angchaisuksiri P, Bunyaratavej A, Rojanasthein S, Atichartakarn V.

J Med Assoc Thai. 2000 Mar;83 Suppl 1:S95-100.

PMID:
10865414
[PubMed - indexed for MEDLINE]
3.

Uncontrolled thrombocytosis in chronic myeloproliferative disorders.

Kessler CM, Klein HG, Havlik RJ.

Br J Haematol. 1982 Jan;50(1):157-67.

PMID:
6976793
[PubMed - indexed for MEDLINE]
4.

Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients.

Wehmeier A, Daum I, Jamin H, Schneider W.

Ann Hematol. 1991 Aug;63(2):101-6.

PMID:
1912029
[PubMed - indexed for MEDLINE]
5.

Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases.

Buss DH, Cashell AW, O'Connor ML, Richards F 2nd, Case LD.

Am J Med. 1994 Mar;96(3):247-53.

PMID:
8154513
[PubMed - indexed for MEDLINE]
6.

Template bleeding time and clinical hemorrhage in myeloproliferative disease.

Murphy S, Davis JL, Walsh PN, Gardner FH.

Arch Intern Med. 1978 Aug;138(8):1251-3.

PMID:
277084
[PubMed - indexed for MEDLINE]
7.

Therapeutic dilemmas: balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD).

Murphy S.

Thromb Haemost. 1997 Jul;78(1):622-6. Review.

PMID:
9198227
[PubMed - indexed for MEDLINE]
8.

Thrombosis and hemorrhage in thrombocytosis: evaluation of a large cohort of patients (357 cases).

Randi ML, Stocco F, Rossi C, Tison T, Girolami A.

J Med. 1991;22(4-5):213-23.

PMID:
1787383
[PubMed - indexed for MEDLINE]
9.

Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis.

Talpaz M, Kurzrock R, Kantarjian H, O'Brien S, Gutterman JU.

Am J Med. 1989 May;86(5):554-8.

PMID:
2712063
[PubMed - indexed for MEDLINE]
10.

Thrombotic and hemorrhagic complications in chronic myeloproliferative disorders.

Sagripanti A, Ferretti A, Nicolini A, Carpi A.

Biomed Pharmacother. 1996;50(8):376-82.

PMID:
8952859
[PubMed - indexed for MEDLINE]
11.

Propensity for hemorrhage and thrombosis in chronic myeloproliferative disorders.

Kessler CM.

Semin Hematol. 2004 Apr;41(2 Suppl 3):10-4. Review.

PMID:
15190517
[PubMed - indexed for MEDLINE]
12.

Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.

Fruchtman SM, Petitt RM, Gilbert HS, Fiddler G, Lyne A; Anagrelide Study Group.

Leuk Res. 2005 May;29(5):481-91. Epub 2005 Jan 21.

PMID:
15755500
[PubMed - indexed for MEDLINE]
13.

The role of platelets in the pathogenesis of thrombosis and hemorrhage in patients with thrombocytosis.

Walsh PN, Murphy S, Barry WE.

Thromb Haemost. 1977 Dec 15;38(4):1085-96.

PMID:
579686
[PubMed - indexed for MEDLINE]
14.

Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.

Steurer M, Gastl G, Jedrzejczak WW, Pytlik R, Lin W, Schlögl E, Gisslinger H.

Cancer. 2004 Nov 15;101(10):2239-46.

PMID:
15476273
[PubMed - indexed for MEDLINE]
Free Article
15.

Simultaneous study of platelets and phagocytes in myeloproliferative disorders.

Laharrague PF, Corberand JX, Fillola G, Boneu BP, Pris JF.

Biomed Pharmacother. 1984;38(9-10):462-5.

PMID:
6597727
[PubMed - indexed for MEDLINE]
16.

Hemorrhagic and thrombotic complications in patients with myeloproliferative diseases.

Vignal CV, Lourenço DM, Noguti MA, Chauffaille Mde L, Kerbauy J.

Sao Paulo Med J. 1997 Nov-Dec;115(6):1575-9.

PMID:
9640794
[PubMed - indexed for MEDLINE]
17.

Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function.

Barbui T, Cortelazzo S, Viero P, Bassan R, Dini E, Semeraro N.

Eur J Cancer Clin Oncol. 1983 Nov;19(11):1593-9.

PMID:
6580171
[PubMed - indexed for MEDLINE]
18.

Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia.

Michiels JJ, van Genderen PJ, Lindemans J, van Vliet HH.

Leuk Lymphoma. 1996 Sep;22 Suppl 1:47-56. Review.

PMID:
8951772
[PubMed - indexed for MEDLINE]
19.

Analysis of risk factors: the rationale of the guidelines of the Czech Hematological Society for diagnosis and treatment of chronic myeloproliferative disorders with thrombocythemia.

Schwarz J, Pytlík R, Doubek M, Brychtová Y, Dulícek P, Campr V, Kren L, Penka M.

Semin Thromb Hemost. 2006 Apr;32(3):231-45.

PMID:
16673277
[PubMed - indexed for MEDLINE]
20.

[Association of hemorrhagic and thrombotic phenomena in myeloproliferative syndromes].

Meschengieser SS, Woods AI, Schattner MA, Lazzari MA.

Medicina (B Aires). 1981;41 Suppl:267-73. Spanish. No abstract available.

PMID:
6954340
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk